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Objective: To evaluate the analgesic effectiveness of intra-articular botulinum toxin Type B 
(BoNT/B) in a murine model of chronic degenerative arthritis pain.
Methods and materials: Chronic arthritis was produced in adult C57Bl6 mice by intra-
articular injection of Type IV collagenase into the left knee. Following induction of arthritis, 
the treatment group received intra-articular BoNT/B. Arthritic control groups were treated with 
intra-articular normal saline or sham injections. Pain behavior testing was performed prior to 
arthritis, after induction of arthritis, and following treatments. Pain behavior measures included 
analysis of gait impairment (spontaneous pain behavior) and joint tenderness evaluation (evoked 
pain response). Strength was measured as ability to grasp and cling.
Results: Visual gait analysis showed significant impairment of gait in arthritic mice that 
improved 43% after intra-articular BoNT/B, demonstrating a substantial articular analgesic 
effect. Joint tenderness, measured with evoked pain response scores, increased with arthritis 
induction and decreased 49.5% after intra-articular BoNT/B treatment. No improvement in 
visual gait scores or decrease in evoked pain response scores were found in the control groups 
receiving intra-articular normal saline or sham injections. Intra-articular BoNT/B was safe, and 
no systemic effects or limb weakness was noted.
Conclusions: This study is the first report of intra-articular BoNT/B for analgesia in a murine 
model of arthritis pain. The results of this study validate prior work using intra-articular 
neurotoxins in murine models. Our findings show chronic degenerative arthritis pain can be 
quantitated in a murine model by measuring gait impairment using visual gait analysis scores 
(spontaneous pain behavior) and joint tenderness scores (evoked pain responses). Reduction 
of joint pain seen in this study is consistent with our hypothesis of inhibition of release of pain 
mediators by intra-articular BoNT/B, supporting further investigation of this novel approach 
to treatment of arthritis pain with intra-articular neurotoxins.
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Introduction
There is an ongoing need for new therapies for refractory arthritis pain. Osteoarthritis-
related joint pain is a major cause of physical limitation, disability, morbidity, and 
increased health care utilization for the more than 27 million Americans affected by 
osteoarthritis.1,2 Up to 80% of patients with osteoarthritis have movement limitation 
and 25% cannot perform major activities of daily living.3 Up to 20% of the adult popu-
lation is affected by chronic knee pain and associated disability, with 11% of adults 
with knee osteoarthritis needing help with personal care. Osteoarthritis of the knee 
is currently one of the five leading causes of disability among noninstitutionalized Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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adults.3–5 Additionally, 40% of adults with knee osteoarthritis 
reported their health as “poor” or “fair”.3
The primary focus of osteoarthritis care is joint pain 
management because there are no disease modifying agents 
available for osteoarthritis. Goals of osteoarthritis treat-
ment include improved pain control and maintenance or 
  improvement of joint function. Currently available systemic 
analgesics have a significant risk of potentially serious 
side effects. Insufficient joint pain relief, intolerable drug 
side effects, and adverse drug interactions are limitations 
of available oral analgesics.6,7 Localized therapies with 
  intra-articular corticosteroids and viscosupplementation are 
alternative pain control options, but effects and duration 
may be variable. Minimally invasive surgical intervention 
for patients failing systemic and local therapies includes 
arthroscopic lavage and debridement. However, there 
is increasing evidence that arthroscopic debridement out-
comes may be no better than placebo procedures or   optimized 
  physical and medical therapy.8,9 Joint replacement for severe 
disabling   degenerative arthritis pain carries significant 
  surgical risks, and is often not an option for many patients due 
to comorbid medical conditions or advanced age. As average 
life expectancy continues to increase, the burden of disabling 
degenerative arthritis pain is anticipated to increase as well. 
Safe, effective, chronic arthritis pain treatment remains an 
unmet need for many patients, and represents a growing 
socioeconomic burden in an aging population.10
Osteoarthritis is characterized pathologically by bony 
outgrowths (osteophytes), changes in subchondral and mar-
ginal bone, bone marrow edema, and damage to articular 
cartilage surfaces, leading to loss of joint space and joint 
misalignment. Soft tissue changes include variable degrees 
of synovial inflammation, capsular thickening, and liga-
ment laxity.11,12 The periosteum and subchondral and mar-
row bone are richly innervated with sensory fibers, but our 
current understanding of the cause of arthritis pain remains 
limited. Most chronic arthritis research and treatment has 
focused on the degenerative mechanisms and immunologic 
processes associated with progressive joint damage, rather 
than the pathogenesis of arthritis-induced pain. Studies of the 
mechanisms of pain in arthritis have shown that inflammation 
within joints causes both peripheral and central sensitization 
of neurons, with spontaneous joint pain at rest and hyper-
algesia.13 Given this peripheral sensitization, arthritis pain 
may be treated effectively by intra-articular neurotoxins. 
Reduction in arthritis pain following use of intra-articular 
botulinum toxin Type A (BoNT/A) in humans and in murine 
models of arthritis has been reported.14–17 We hypothesized 
that botulinum toxin Type B (BoNT/B) would also reduce 
chronic arthritic knee pain. Intra-articular BoNT/B is another 
option for arthritis pain control that may be superior to other 
BoNT serotypes. To test this hypothesis, we measured the 
effect of intra-articular BoNT/B on arthritis pain in a murine 
model of chronic degenerative arthritis.
Methods
Animal subjects
Forty C57B16 mice (Jackson Laboratories, Bar Habor, ME) 
aged 6–8 weeks old were used in this animal study which 
was approved by the Minneapolis Veterans Affairs Medical 
Center Institutional Animal Care and Utilization Commit-
tee. The animals were housed in groups of eight animals in 
the Animal Care and Research Facility at the Minneapolis 
Veterans Affairs Medical Center, a facility approved by the 
Association for Assessment and Accreditation of Laboratory 
Animal Care International. The care and studies of these 
animals were performed in accordance with the guidelines 
established in the Guide for the Care and Use of Laboratory 
Animals (The National Academies Press, USA).
collagenase-induced chronic 
degenerative arthritis model
Chronic arthritis pain was produced in 40 C57Bl6 mice 
by intra-articular injection of 10 IU Type IV collagenase 
(Worthington Biomedical Corporation, Lakeville, NJ) in 
10 µL normal saline into the left knee. We used a 30 gauge 
needle with a customized sheath that limited depth of needle 
penetration to 2.5 mm. The injection was performed through 
the midline of the patellar tendon just inferior to the patella 
to ensure accurate entry into the articular space of the knee. 
Prior to injection, the area was shaved and sterilized with 
alcohol and animals were anesthetized with isofluorane 
inhalation. Arthritis was evaluated four weeks after intra-
articular collagenase injection. Mice were evaluated for 
spontaneous pain behavior, evoked pain behavior, and safety 
using a battery of standardized measures described below. 
The timepoints for behavioral testing were prior to and after 
induction of arthritis, and after treatment of arthritis pain.
spontaneous pain behavior: measurement 
of gait impairment
Visual gait analysis was performed by walking the   animals 
on a motorized treadmill (Columbus Instruments,   Columbus, 
OH) at a constant speed of 17 cm/sec for a total time 
of 20 seconds. Gait was evaluated visually and graded Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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  semiquantitatively on a scale of 0–4 as a consensus score 
among three experienced examiners. Gait was defined as 
normal (4) if the animal was easily able to maintain a con-
sistent speed while walking on the treadmill. Scores of 3, 2, 
and 1 were given for minimal, moderate, and significant gait 
impairment, respectively (Table 1).
evoked pain behavior: measurement  
of joint tenderness
Evoked pain behavior (tenderness) was measured by 
  tallying fights (kicks, attempts to break from restraint) and 
vocalizations for one minute in response to repeated firm 
palpation of the knee. A single examiner performed all 
examinations and was blinded as to treatment group assign-
ment. A Palpometer® (Palpometer Systems, Inc., Victoria, 
BC) was used to train the examiner to apply consistent and 
precise firm pressure, defined as a level of 4 on the Palpom-
eter (1100 gf/cm2 = 15.6 psi). Pressure of this magnitude 
was high enough to elicit a significant pain response from 
arthritic joints, but not from normal joints. Both the right 
(normal) and left knee (arthritic) were examined, with the 
right knee serving as an internal control. The normal right 
knee was always examined first. In preliminary experiments 
with tenderness testing, our group found slightly elevated 
tenderness scores in the nonarthritic knee when the arthritic 
knee was examined first.
safety
Systemic adverse effects were assessed by observing for 
anorexia, dehydration, hunched posture, poor grooming, 
coat changes, or other evidence of poor animal well-being. 
Given botulinum toxin’s known effects of muscle weakness, 
strength was measured at baseline before induction of arthritis 
pain, four weeks after intra-articular injection of collagenase 
(arthritic state), and after intra-articular treatments. Change 
in muscle strength was measured by the ability to grasp a 
wire grid against resistance and cling to it while inverted. 
Grasp ability was tested by applying traction to the animal’s 
tail parallel to the wire grid. Cling ability was tested by 
inverting the mouse on the wire grid three times with tail 
held down to wire grid. Both grasp and cling ability were 
graded on a 0–4 scale. A score of 0 represented inability to 
grasp or cling to the wire grid. A score of 4 represented a 
strong grip against resistance and no instability with inver-
sion (Tables 2 and 3).
intra-articular neurotoxin and controls
Four weeks following intra-articular injection of 10 IU col-
lagenase into the left knee, 17 animals were treated with intra-
articular BoNT/B (Myobloc®, Solstice Neurosciences Inc., 
South San Francisco, CA) 0.02 IU in 5 µL of normal saline 
into the arthritic left knee. Gait assessment, joint tenderness, 
and strength examinations were performed three days fol-
lowing intra-articular BoNT/B to allow time for the toxin 
to take effect. Control groups consisted of arthritic animals 
treated with either intra-articular normal saline or a sham 
injection to the left knee at the four-week time point. Seven 
animals received 5 µL or 10 µL intra-articular normal saline 
and eight animals received sham injections. Gait impairment 
assessment, joint tenderness, and strength examinations were 
performed three days following intra-articular normal saline 
or sham injections.
histologic examination of normal  
and arthritic knees
Following conclusion of the study, right (normal) and left 
(arthritic) knees of representative animals were examined 
for histologic evidence of degenerative arthritis. The ani-
mals were humanely euthanized using C02 gas and second-
ary exsanguination. Right and left lower extremities were 
dissected. Articular specimens were fixed in 10% buffered 
formalin for 24 hours and decalcified in 10% ethylenediamine  Table 1 gait impairment criteria
0 Mouse refuses to walk on treadmill
1 Mouse walks up to 30% of the allotted time without touching 
dividers, jumping, splaying its legs, or dragging hindquarters; 
displays severe inconsistencies in gait
2 Mouse walks up to 60% of the allotted time without touching 
dividers, jumping, splaying its legs, or dragging hindquarters; 
displays moderate inconsistencies in gait
3 Mouse walks up to 90% of the allotted time without touching 
dividers, jumping, splaying its legs, or dragging hindquarters; 
displays minor inconsistencies in gait
4 Mouse walks the entire time without touching dividers, 
jumping, splaying its legs, or dragging hindquarters; displays 
no inconsistencies in gait.
Table 2 grasp impairment criteria
0 Mouse gives no resistance to being pulled across screen; 
unable to grasp the screen
1 Minimal force needed to pull the mouse across the 
screen; significant difficulty grasping the screen
2 Moderate force needed to pull the mouse across the 
screen; moderate difficulty grasping the screen
3 Significant force needed to pull the mouse across the 
screen; minimal difficulty grasping the screen
4 Full force needed to pull the mouse across the screen; 
no difficulty grasping the screen.Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
164
Anderson et al
tetraacetic acid for two weeks before paraffin embedding. 
Paraffin-embedded specimens were then sectioned and 
stained with hematoxilyn and eosin.
statistical methods
The unpaired Student’s t-test was used to compare groups, 
ie, prior to induction of arthritis, arthritic, treated, and normal 
right knee values. Comparisons were made between normal, 
arthritic, BoNT/B-treated arthritic, and saline-treated arthritic 
controls using unpaired Student’s t-tests. The significance 
level was selected at a P value of 0.05.
Results
Pain behaviors following induction 
of arthritis by intra-articular collagenase
Arthritis was successfully induced in 40 mice by intra-
articular injection of 10 IU collagenase in 10 µL normal 
saline into the left knee. Animals were examined four 
weeks after intra-articular collagenase for development of 
arthritis. Significant alterations in gait due to arthritis pain 
was demonstrated by decline in visual gait score from 3.50 
(SEM = 0.076) to 2.36 (SEM = 0.112), P , 0.0001. Evoked 
pain behavior scores induced by palpation of the painful 
arthritic knee were increased significantly, from a baseline 
total score of 1.83 (SEM = 0.405) to 7.23 (SEM = 0.953, 
P , 0.0001, Figure 1).
effects of intra-articular BonT/B  
on pain behavior measures following 
induction of arthritis
Seventeen mice with collagenase-induced arthritis pain of 
the left knee were treated at four weeks with intra-articular 
injection of 0.02 IU BoNT/B in 5 µL normal saline into the 
affected knee. Animals were examined three days follow-
ing intra-articular BoNT/B to allow time for appearance of 
botulinum effects. There were significant improvements in 
both spontaneous pain behavior measures (visual gait impair-
ment scores) and evoked pain behaviors (joint tenderness 
to palpation scores). Visual gait analysis score improved 
by 43% (P = 0.0419), and the evoked pain response score 
decreased by 49.5% (P = 0.0134) following intra-articular 
BoNT/B (Figure 1).
effects of intra-articular normal saline 
and sham injections following induction 
of arthritis
Treatment control groups included seven arthritic mice 
receiving either 5 or 10 µL intra-articular normal saline 
into the left knee, and eight arthritic mice receiving sham 
injections into the left knee at four weeks following intra-
articular collagenase. Animals were examined three days 
following either normal saline or sham injections and com-
pared with untreated arthritic animals (n = 40). There were 
no significant changes in spontaneous pain behavior scores 
or evoked pain behavior scores in these control animals. No 
significant change in visual gait analysis score was noted 
following either intra-articular normal saline or sham injec-
tions (P = 0.225 and P = 0.1921, respectively). Evoked pain 
response scores following intra-articular normal saline or 
sham injections did not change significantly (P = 0.9043 
and P = 0.5355, respectively, Figure 1).
normal right knee controls
Throughout all stages of this study the right knee was a nor-
mal, nonarthritic internal control. After induction of arthritis, 
evoked pain behavior response score in the contralateral knee 
increased from a baseline mean of 0.83 (SEM = 0.208) to 
2.65 (SEM = 0.728. P = 0.0083).
safety
Grasp and cling strength were measured to monitor safety 
because of the known effects of muscle weakness caused by 
botulinum toxins. Strength was measured at baseline, after 
development of arthritis, and in the post-treatment state. 
Strength was evaluated by measuring ability to grasp and 
cling. Forty mice were examined at baseline and four weeks 
following intra-articular collagenase (arthritic state). Strength 
assessment showed a significant decline in both measures 
following induction of arthritis pain, prior to treatment with 
intra-articular BoNT/B. Grasp scores declined 34% from a 
baseline score of 3.83 (SEM = 0.120) to 2.53 (SEM = 0.155, 
P , 0.0001). Cling scores also declined 34% from a base-
line score of 3.67 (SEM = 0.129) to 2.43 (SEM = 0.168, 
P = 0.0003). After induction of arthritis and three days 
following intra-articular BoNT/B into the left knee, grasp 
scores improved 22% (n = 17, P = 0.0704), cling scores 
Table 3 cling impairment criteria
0 Mouse cannot hold on when the screen is tilted vertically
1 Mouse has shown that it can grip the screen when vertical but 
falls during every inversion
2 The mouse falls off the screen during two inversions or falls off 
the screen during one inversion and displays instability during 
the other two inversions
3 The mouse falls off the screen once or shows instability during 
two inversions
4 The mouse does not display instability with any inversion.Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
165
Botulinum toxin in knee arthritis
improved 23% (n = 17, P = 0.2752), although not reaching 
statistical significance in this small study. The seven animals 
that received intra-articular normal saline injections had no 
significant change in grasp or cling scores compared with 
the arthritic state (P = 0.3964 and P = 0.7457 respectively, 
Figure 2). Eight animals that received sham injections had 
no change in grasp (P = 0.5637), but did have a significant 
decrease in ability to cling (P = 0.0019). No signs of anorexia, 
dehydration, hunched posture, poor grooming, coat changes, 
or other evidence of poor animal well-being were noted in 
any animals at any point during the study.
histologic examination of normal  
and arthritic knees
Following conclusion of the study, right (normal) and left 
(arthritic) knees of representative animals were examined for 
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Figures 1 A) evoked pain response: Measurement of joint tenderness (left knee) and B) spontaneous pain behavior: Measurement of gait changes.
Notes: seventeen mice with collagenase-induced arthritis of the left knee were treated at four weeks with intra-articular botulinum neurotoxin Type B (Myobloc®) 0.02 iU in 
5 µL of normal saline in the arthritic left knee. Animals were examined three days following intra-articular botulinum neurotoxin Type B to allow time for botulinum effects. 
Significant improvements in evoked pain response and spontaneous pain behavior (visual gait analysis) were noted following intra-articular botulinum neurotoxin Type B 
(P = 0.0134 and P = 0.0419, respectively). gait improved by 43%, and evoked pain response was decreased by 49.5% following intra-articular botulinum neurotoxin Type B 
treatment. Treatment control groups included seven arthritic mice receiving either 5 or 10 µL intra-articular normal saline in the arthritic left knee at four weeks following 
intra-articular collagenase. Animals were examined three days following normal saline injections and compared with untreated arthritic animals (n = 40). No significant 
change in evoked pain response or spontaneous pain behavior (visual gait analysis) was noted following intra-articular normal saline (P = 0.9043 and P = 0.2250, respectively).
Abbreviations: naïve, 40 animals prior to induction of arthritis in the left knee; Arthritic, 40 animals four weeks post intra-articular collagenase into the arthritic left knee; 
Arth/BonT/B, 17 animals four weeks post intra-articular collagenase into the left knee (arthritic), three days post intra-articular botulinum neurotoxin Type B into the arthritic 
left knee; Arth/saline, seven animals four weeks post intra-articular collagenase into the left knee (arthritic), three days post intra-articular saline into the arthritic left knee.Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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Figure 2 safety assessment: Limb strength.
Notes: The 17 animals receiving intra-articular botulinum neurotoxin Type B were 
assessed  for  changes  in  strength  three  days  following  intra-articular  botulinum 
neurotoxin Type B. No significant change in grasp or cling scores were noted 
following intra-articular botulinum neurotoxin Type B compared with untreated 
arthritic  animals  (P  =  0.0704  and  P  =  0.2752,  respectively).  The  seven  animals 
receiving intra-articular normal saline injections had no significant change in grasp or 
cling scores (P = 0.3964, P = 0.7457, respectively).
Abbreviations: arthritic, 40 animals four weeks post intra-articular collagenase 
into the arthritic left knee; Arth/BonT B, 17 animals four weeks post intra-articular 
collagenase into the left knee (arthritic), three days post intra-articular botulinum 
neurotoxin Type B into the arthritic left knee; Arth/saline, seven animals four weeks 
post intra-articular collagenase into the left knee (arthritic), three days post intra-
articular saline into the arthritic left knee.
histologic evidence of degenerative arthritis. Hematoxilyn 
and eosin staining of knees revealed irregularities and thin-
ning of articular cartilage and early osteophyte formation 
compared with normal knees, ie demonstrating changes 
consistent with osteoarthritis (Figures 3 and 4).
Discussion
This study is the first report of intra-articular BoNT/B for 
analgesia in a murine model of arthritis pain. The results 
of this study validate prior work using intra-articular 
  neurotoxins in murine models.16 Our findings show chronic 
degenerative arthritis pain can be quantified in a murine 
model by measuring gait impairment with visual gait   analysis 
scores (ie, spontaneous pain behavior) and joint tender-
ness scores (ie, evoked pain responses). Visual gait analysis 
showed significant impairment of gait in arthritic mice that 
improved 43% after intra-articular BoNT/B, demonstrating 
a substantial articular analgesic effect. Joint inflammation 
is not a prominent feature of degenerative arthritis, but joint 
tenderness, measured with evoked pain response scores, 
increased with arthritis induction and decreased 49.5% after 
intra-articular BoNT/B treatment. These changes in joint 
tenderness were clinically and statistically significant even 
with the relatively small animal numbers used in this study. 
Reduction of joint pain seen in this study is consistent with 
our hypothesis of inhibition of release of pain mediators by 
intra-articular BoNT/B.
Figure 3 hematoxylin and eosin stained normal right knee.
Note: normal-appearing articular cartilage (arrowhead), meniscus (arrow), and 
synovium (asterisk).
Figure 4 Arthritic left knee stained with hematoxylin and eosin.
Note:  irregularities  and  thinning  of  articular  cartilage  (arrowheads)  and  early 
osteophyte formation (arrow) consistent with degenerative arthritis.
There was a small increase in the evoked pain behavior 
response score in the contralateral nonarthritic right knee that 
was not clinically significant. This interesting pain response 
in the normal contralateral limb is similar to findings noted 
by other groups studying monoarthritis in murine models. 
Lam et al reported that substance P exacerbated and spread 
the early signs of disease, such as increased blood flow and 
vascular permeability, to contralateral joints.18
Role for intra-articular  
botulinum therapy
Botulinum neurotoxin (BoNT) is produced by Clostridium 
botulinum as a complex of proteins containing the neurotoxic Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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moiety associated with nontoxic components. There are seven 
serologically distinct BoNT serotypes that all act by inhibiting 
release of signal chemicals packaged in neuronal vesicles.19 
The exocytosis of neuronal signal chemicals is dependent on 
the function of the N-ethylmaleimide-sensitive factor attach-
ment protein receptor complex, collectively called the soluble 
N-ethylmaleimide-sensitive factor activating protein receptor 
(SNARE) proteins.19,20 All serotypes of BoNT cleave SNARE 
proteins. The specific target site within the SNARE complex 
is dependent on the BoNT serotype.19 Although all BoNTs 
act by disabling SNARE-associated exocytosis, the potencies 
and characteristics of their actions vary.19–21 Botulinum toxins 
affect striated muscle by creating a chemical denervation that 
is temporary and reversible through highly potent inhibition 
of acetylcholine release at the neuromuscular junction.20 Ace-
tylcholine is not the only neurotransmitter affected by BoNTs. 
BoNTs have also been found to affect the release of multiple 
SNARE-dependent neuropeptides, including substance P, 
glutamate, and calcitonin gene-related peptide, all important 
mediators of articular pain transmission.15,22
BoNTs are the most potent neurotoxins known. However, 
small doses are successful as cosmetic and musculoskeletal 
therapies. Currently, BoNT/A and BoNT/B are the best 
characterized and most used clinically. BoNT/A injections 
are analgesic for painful muscle contractions associated with 
cervical dystonia, migraine/tension headaches, and myo-
fascial pain syndromes.23 In BoNT/A treatment of painful 
soft tissue syndromes, pain relief preceded the resolution 
of muscle contractions, suggesting that BoNTs may have 
antinociceptive effects independent of known effects on 
neuromuscular junctions.24 BoNT/A inhibited capsaicin-
stimulated release of substance P from embryonic rat dorsal 
root ganglia neurons in culture.25 Subcutaneous BoNT/A paw 
injections in a formalin-induced rat model of pain reduced 
electrical excitations and c-fos expression in the spinal cord, 
and reduced edema and tissue glutamate release.26
Efficacy of intra-articular BoNT/A for refractory arthritis 
pain in humans, and in murine models of arthritis joint pain, 
has been reported recently. Intra-articular BoNT/A reduced 
lower extremity arthritis pain by an average of 55%, and 
shoulder pain by an average of 71% in a study of 11 patients 
with chronic arthritis pain refractory to intra-articular corti-
costeroids, with no noted adverse effects.14 In another study 
of patients with refractory axial skeletal pain, eight of 11 
reported a decrease in pain score, improved activities of daily 
living, and range of motion following BoNT injections. These 
BoNT injections for axial skeletal pain provided longer last-
ing pain relief than corticosteroid injections.27 Similar results 
were found in a randomized placebo-controlled trial of 
BoNT/A in chronic severe shoulder pain.17 Another random-
ized controlled trial found that intra-articular BoNT/A was 
as effective as intra-articular corticosteroids for chronic knee 
pain.28 Krug et al have reported significant analgesic effects 
of intra-articular BoNT/A in murine models of chronic 
inflammatory arthritis.16 Analgesic effects were not found 
in the acute carrageenan arthritis pain model.
Intra-articular BoNT/B was safe, with no weakness of 
limb muscles or systemic effects noted. This finding of 
safety confirms our prior work with intra-articular BoNT/A 
in murine arthritis models and small human studies. It is 
possible that higher doses of intra-articular BoNT/B could 
be used to optimize analgesic effects. The current study does 
have the noted weakness that our visual gait analysis system 
may not be sensitive enough to measure full treatment effect, 
therefore future studies will incorporate computerized digital 
gait analysis. Additionally, in this preliminary study, the 
duration of action of intra-articular BoNT/B has not been 
fully explored. Evaluation of dose response and duration of 
effect are future research directions for our group. Mixtures 
of various intra-articular botulinum serotypes may provide 
faster onset of action and longer duration of effects. Such 
mixtures may prove useful in other types of articular pain.
This study supports the hypothesis that chronic arthritis 
pain may be amplified by neuropeptide release in the periph-
ery. Inhibition of neuropeptide release may have altered noci-
ceptor function, and reduced pain generation and neurogenic 
inflammation. This selective chemodenervation of articular 
pain fibers with intra-articular injection of neurotoxins is a 
novel local approach to treatment of arthritis joint pain. Inter-
ruption of neuropeptide release by intra-articular BoNT/B 
appeared to decrease pain responses in the joint and improve 
gait abnormalities. The results of this study support further 
investigation of this novel approach to treatment of arthritis 
pain with intra-articular neurotoxins.
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